STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

MNKD MANNKIND CORPORATION StockScouter® Report

4

StockScouter® Score

MANNKIND CORPORATION, a small cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for MNKD. Positive/Neutral

 

Concerns

  • The multi-period measure of relative price change and consistency is well below average. Negative
  • Two or more executives, directors or major shareholders sold a large number of shares recently. Very negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be in favor, growth stocks will be in favor, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 40% done.
Progress: 40% done.
Low
High

Core Model Grades

B
F
D
F

Previous Ratings

4
5
5